{"nctId":"NCT03216226","briefTitle":"A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus","startDateStruct":{"date":"2017-06-28","type":"ACTUAL"},"conditions":["Hypoglycemia","Diabetes Mellitus, Type 1"],"count":112,"armGroups":[{"label":"dasiglucagon (ZP4207)","type":"EXPERIMENTAL","interventionNames":["Drug: dasiglucagon"]},{"label":"GlucaGen","type":"EXPERIMENTAL","interventionNames":["Drug: GlucaGen"]}],"interventions":[{"name":"dasiglucagon","otherNames":["ZP4207"]},{"name":"GlucaGen","otherNames":["GlucaGen HypoKit"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities (trial-related activities are any procedure that would not have been performed during normal management of the patient)\n* Availability for the entire trial period\n* Age between 18 and 70 years, both inclusive\n* Male or female patients with T1DM for at least 1 year. Diagnostic criteria as defined by the American Diabetes Association\n* Hemoglobin A1c (HbA1c) \\<10%\n* Stable anti-diabetic treatment for at least 1 month (e.g. within 10% insulin dose adjustment)\n\nExclusion Criteria:\n\n* Previous administration of dasiglucagon (previously referred to as ZP4207)\n* Known or suspected allergy to trial medication(s) or related products\n* History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema)\n* Previous participation (randomization) in this trial\n* Females who are pregnant according to a positive pregnancy test, actively attempting to get pregnant, or are lactating\n* Patients on a closed loop artificial pancreas\n* Receipt of any investigational drug within 3 months prior to screening\n* Active malignancy within the last 5 years\n* Congestive heart failure, New York Heart Association class II-IV\n* Inadequately treated blood pressure as defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥90 mmHg at screening\n* Current bleeding disorder, including use of anticoagulant treatment\n* Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin-secreting pancreas tumor)\n* Known or suspected HIV infection\n* Use of a systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial\n* Use of systemic corticosteroids, anti-inflammatory biological agents, kinase inhibitors or other immune modulating agents within the last 3 months prior to screening\n* Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks prior to screening\n* A positive result in the alcohol and/or urine drug screen at the screening visit. Significant history of alcoholism or drug abuse as judged by the investigator or consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day for women.\n* Surgery or trauma with significant blood loss within the last 2 months prior to screening\n* Use of prescription or non-prescription medications known to cause QT prolongation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients With ADA","description":"Percentage of the combined results of treatment-induced ADA-positive patients and treatment-boosted ADA-positive patients out of the total number of evaluable patients. ADA = antidrug antibodies.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Treatment-induced ADA","description":"Percentage of the total number of evaluable patients that were ADA negative at baseline and ADA positive after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Treatment-boosted ADA","description":"Percentage of baseline ADA-positive patients with significant increases (≥5-fold) in ADA titre after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Characterization of ADA Response - Neutralizing Activity","description":"Percentage of ADA positive patients with ADA neutralizing activity. ADA = antidrug antibodies.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Characterization of ADA Response - Titer of Neutralizing Activity","description":"Titre of neutralizing activity of ADA positive patients. ADA = antidrug antibodies.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Characterization of ADA Response - Cross-reactivity","description":"Percentage of ADA positive patients with cross-reactivity towards endogenous glucagon. ADA = antidrug antibodies.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Characterization of ADA Response - Timing","description":"The timing of detected ADA response. ADA = antidrug antibodies.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Characterization of ADA Response - Duration","description":"The Duration of detected ADA response. ADA = antidrug antibodies.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Pharmacokinetics - Area Under the Plasma Concentration Curve","description":"Area under the plasma concentration curve (AUC) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"425","spread":"220"},{"groupId":"OG001","value":"548","spread":"226"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"499","spread":"371"},{"groupId":"OG001","value":"546","spread":"181"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics - Area Under the Plasma Concentration Curve","description":"Area under the plasma concentration curve (AUC) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1560","spread":"615"},{"groupId":"OG001","value":"1290","spread":"434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1640","spread":"611"},{"groupId":"OG001","value":"1290","spread":"379"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics - Maximum Plasma Concentration","description":"Maximum plasma concentration (Cmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1390","spread":"609"},{"groupId":"OG001","value":"1490","spread":"537"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1820","spread":"2460"},{"groupId":"OG001","value":"1430","spread":"498"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics - Time to Maximum Plasma Concentration","description":"Time to maximum plasma concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.483","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics - Area Under the Effect Curve","description":"Plasma glucose profiles, area under the effect curve (AUE) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.799","spread":"0.449"},{"groupId":"OG001","value":"0.886","spread":"0.504"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.869","spread":"0.375"},{"groupId":"OG001","value":"0.895","spread":"0.511"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics - Area Under the Effect Curve","description":"Plasma glucose profiles, area under the effect curve (AUE) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"2.42"},{"groupId":"OG001","value":"5.86","spread":"3.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.47","spread":"2.28"},{"groupId":"OG001","value":"6.04","spread":"2.63"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics - Change From Baseline Plasma Glucose","description":"Change from baseline plasma glucose to maximum plasma glucose (CEmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.25","spread":"2.5"},{"groupId":"OG001","value":"6","spread":"3.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.88","spread":"2.43"},{"groupId":"OG001","value":"6.21","spread":"2.65"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics - Time to Maximum Plasma Glucose Concentration","description":"Time to maximum plasma glucose concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics - An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment","description":"An increase in the plasma glucose concentration of ≥20 mg/dL within 30 minutes after treatment at visit 2 and visit 4. Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"51","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"47","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":57},"commonTop":["Hypoglycemia","Nausea","Vomiting","Viral upper respiratory tract infection","Headache"]}}}